Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.22.2.2
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 25,147 $ 8,517 $ 59,140 $ 51,226
Collaboration and License Agreements and Supply Agreements        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 25,147 8,517 59,140 51,226
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 4,343 1,118 8,774 7,784
Collaboration and License Agreements and Supply Agreements | Merck Sharp & Dohme Corporation ("Merck")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 10,157 6,414 11,367 38,175
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'' )        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 166 249 2,200 2,844
Collaboration and License Agreements and Supply Agreements | Astellas Pharma Inc. ("Astellas")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 4,985   4,985  
Collaboration and License Agreements and Supply Agreements | Vaxcyte        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 1,496 736 2,814 2,423
Collaboration and License Agreements and Supply Agreements | BioNova Pharmaceuticals, Ltd. ("BioNova")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 4,000   4,000  
Collaboration and License Agreements and Supply Agreements | Tasly Biopharmaceuticals Co., Ltd. ("Tasly")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue     25,000  
BMS Agreement and the 2018 BMS Master Services Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 4,343 1,118 8,774 7,784
BMS Agreement and the 2018 BMS Master Services Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 107 249 591 762
BMS Agreement and the 2018 BMS Master Services Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 4,236 869 8,183 7,022
2020 Merck Master Services Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 10,157 6,414 11,367 38,175
2020 Merck Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue   3,506 862 30,889
2020 Merck Master Services Agreement | Contingent Payment Earned        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 10,000   10,000  
2020 Merck Master Services Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 136 419 402 2,328
2020 Merck Master Services Agreement | Financing Component on Unearned Revenue        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue   149   561
2020 Merck Master Services Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 21 2,340 103 4,397
2019 EMD Serono Supply Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 166 249 2,200 2,844
2019 EMD Serono Supply Agreement | Contingent Payment Earned        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue       2,000
2019 EMD Serono Supply Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 78 214 494 503
2019 EMD Serono Supply Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 88 35 1,706 341
Supply Agreement | Vaxcyte        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 1,496 736 2,814 2,423
Supply Agreement | Vaxcyte | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 651 247 1,794 716
Supply Agreement | Vaxcyte | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 845 $ 489 1,020 $ 1,707
Astellas License and Collaboration Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 4,985   4,985  
Astellas License and Collaboration Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 1,925   1,925  
Astellas License and Collaboration Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 809   809  
Astellas License and Collaboration Agreement | Financing Component on Unearned Revenue        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 2,251   $ 2,251